跳至主要内容
临床试验/NCT00134498
NCT00134498已完成3 期

Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia

Pfizer44 个研究点 分布在 2 个国家目标入组 160 人开始时间: 2005年2月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
160
试验地点
44
主要终点
Change in HDL-C and non-HDL-C levels

研究概览

简要总结

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.

详细描述

For additional information please call: 1-800-718-1021

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of Fredrickson Type IV Hypertriglyceridemia

排除标准

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study

结局指标

主要结局

Change in HDL-C and non-HDL-C levels

次要结局

  • Changes in levels of other lipid and biomarkers.

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (44)

Loading locations...

相似试验

A Study Comparing The Efficacy & Safety Of... | 临床试验